Jump to content

Imvanex

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by ClueBot NG (talk | contribs) at 21:00, 3 December 2016 (Reverting possible vandalism by 2607:FEA8:131F:EE9D:15AB:8AA2:23D4:345C to version by DePiep. Report False Positive? Thanks, ClueBot NG. (2858495) (Bot)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Imvanex
Vaccine description
TargetSmallpox
Vaccine typeAttenuated
Clinical data
Trade namesImvanex, Imvamune
Routes of
administration
subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • none

Imvanex (Modified Vaccinia Ankara – Bavarian Nordic) is a non-replicating smallpox vaccine developed and manufactured by Bavarian Nordic. It was approved in the European Union for active immunization against smallpox disease in adults in 2013,[1] and has also been approved in Canada where it is marketed as Imvamune.[2] On its path for the approval in the U.S., Imvamune undergoes additional series of evaluation studies.[3][4]

Imvanex contains a modified form of the vaccinia virus, Modified vaccinia Ankara, which does not replicate in human cells and hence does not cause the serious side effects that are seen with replicating smallpox vaccines. These replicating vaccines use different strains of the vaccinia virus, which all replicate in humans, and are not recommended for persons with immune deficiencies and exfoliative skin disorders such as eczema or atopic dermatitis. Vaccines containing vaccinia viruses were used effectively in the campaign to eradicate smallpox. Because of similarities between vaccinia and the smallpox virus, the antibodies produced against vaccinia have been shown to protect against smallpox. In contrast to replicating smallpox vaccines, which are applied by scarification using a bifurcated needle, Imvanex is administered by injection via the subcutaneous route.

References

  1. ^ "Summary of the European public assessment report". European Medicines Agency. Retrieved 2014-10-02.
  2. ^ "Products for Human Use. Submission #144762". Register of Innovative Drugs. Health Canada. Retrieved 2014-10-30.
  3. ^ "Infectious Diseases: Clinical Trials". Bavarian Nordic. Retrieved 2014-10-30.
  4. ^ "Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 2014-10-30.